← Back to all trials
Recruiting
NCT05711459
Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
Conditions: Drug-Induced Acute Liver Injury
Sex: All
Phase: NA
Enrollment: 5405
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Location: China
Summary
The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.
Eligibility Criteria
Inclusion Criteria:The acute liver injury caused by anti-tumor drugsThe RUCAM assessment scale ≥6The liver injury must in the acute phaseMust be treated with bicyclol tabletsMust sign informed consent -Exclusion Criteria:This acute liver injury caused by non-anti-tumor drugsPregnant womenLactating womenChildbearing age women are plan to conceive
Source: ClinicalTrials.gov (NCT05711459). StuddyBuddy aggregates publicly available trial information.
